Zydus settles US Mirabegron patent dispute with Astellas for $120 million
Zydus Lifesciences and its US subsidiary have settled patent litigation with Astellas Pharma over Astellas' Myrbetriq. Zydus will pay Astellas $120 million upfront and a per-unit licensing fee on generic Mirabegron sales until September 2027. This agreement resolves all disputes and allows Zydus to continue marketing its generic version in the US.